<DOC>
	<DOCNO>NCT02540993</DOCNO>
	<brief_summary>The purpose study evaluate whether oral finerenone ( study drug ) , addition standard daily therapy , effective safe treat patient type 2 diabetes mellitus diabetic kidney disease , compare placebo .</brief_summary>
	<brief_title>Efficacy Safety Finerenone Subjects With Type 2 Diabetes Mellitus Diabetic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Men woman ≥18 year age Subjects Type 2 diabetes mellitus define American Diabetes Association Diagnosis diabetic kidney disease ( DKD ) persistent high albuminuria persistent high albuminuria Runin Screening visit : Pretreated either angiotensinconverting enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) maximal tolerate label dose without adjustment Serum potassium &lt; =4.8 mmol/L . Confirmed significant nondiabetic renal disease , include clinically relevant renal artery stenosis Uncontrolled arterial hypertension ( ie , mean sit systolic blood pressure ( SBP ) ≥170 mmHg , sit diastolic blood pressure ( DBP ) ≥110 mmHg run visit , mean sit SBP ≥160 mmHg , sit DBP ≥100 mmHg screen ) Clinical diagnosis chronic heart failure reduce ejection fraction ( HFrEF ) persistent symptoms New York Heart Association ( NYHA class II IV ) run visit ( class 1A recommendation mineralcorticoid receptor antagonist ( MRAs ) Dialysis acute renal failure within 12 week run visit Renal allograft place schedule kidney transplant within next 12 month Glycated hemoglobin HbA1c &gt; 12 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Kidney disease</keyword>
</DOC>